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2
in an animal is provided. Such a method typically includes
administering, enterally, an effective amount of the Substan
tially pure population of bacteria, of the composition, or of the
foodstuff. Representative animals are humans. In some

PROBOTCS AND METHODS OF
OBTAINING SAME
CROSS REFERENCE TO RELATED
APPLICATIONS

embodiments, the effective amount is from about 10 CFU/

day to about 10' CFU/day.

This application claims benefit under 35 U.S.C. 119(e) to
U.S. Application No. 61/491,406 filed May 31, 2011.
TECHNICAL FIELD

10

This disclosure generally relates to microbiology and,
more specifically, to probiotics.
BACKGROUND

The large intestine of humans harbors a complex, cell rich,
and diverse microbial community consisting of hundreds of
different bacterial species. Included within this microbiota
are organisms whose presence is associated with, or that
contribute to the health of the host, referred to as probiotics.
Probiotics are defined as microbial cell preparations or com
ponents of microbial cells that have a beneficial effect on the
health and well-being of the host. Probiotics have been iden
tified from a number of different genera including, but not
limited to, Lactobacilli, Streptococcus and Bifidobacterium,
which have many species that are indigenous to the human
digestive tract.
Probiotics are thought to exert their beneficial effects by
displacing pathogenic enteric bacteria from the intestinal
mucosa due, at least, in part, to competitive binding. For
example, enteric pathogens such as enteropathogenic
Escherichia coli (EPEC), enterotoxigenic E. coli (ETEC),
Salmonella enteriditis, Yersina pseudotuberculosis and List
eria monocytogenes must be able to Successively colonize an
animals gastrointestinal tract in order to cause disease.

15

25

Unless otherwise defined, all technical and scientific terms
30

used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the methods and
compositions of matter belong. Although methods and mate
rials similar or equivalent to those described herein can be
used in the practice or testing of the methods and composi
tions of matter, suitable methods and materials are described

35

below. In addition, the materials, methods, and examples are
illustrative only and not intended to be limiting. All publica
tions, patent applications, patents, and other references men
tioned herein are incorporated by reference in their entirety.

40

DESCRIPTION OF DRAWINGS

SUMMARY

This disclosure describes novel probiotics, and also
describes novel methods by which such probiotics can be

In another aspect, a method of identifying, in Vivo, a micro
bial strain that has a symbiotic relationship with a prebiotic is
provided. Such a method typically includes administering at
least one dose of the prebiotic to at least one subject; collect
ing a sample comprising gastrointestinal microbiota from the
at least one Subject; and identifying one or more microbial
strains that are increased in the sample collected from the
subject relative to a baseline sample collected from the sub
ject. In some embodiment, the method further includes iso
lating the one or more microbial strains that are increased in
the sample collected from the Subject. In some embodiments,
the method further includes genotyping the one or more
microbial Strains that are increased in the sample collected
from the Subject. In certain instances, the genotyping com
prises sequencing the 16S rDNA. Representative prebiotic
include, without limitation, GOS, fructooligosaccharide
(FOS), and inulin. In some embodiments, the administering
step includes administering the prebiotic to the at least one
Subject in sequentially higher doses over time. In some
embodiments, the administering step lasts for at least a week.
In some embodiments, the sample is a fecal sample.

obtained.

Part A

In one aspect, a Substantially pure population of bacteria is
provided, wherein the bacteria is Bifidobacterium adolescen
tis strain BD1. In some embodiments, the substantially pure
population of bacteria further includes galactooligosaccha
ride (GOS).
In another aspect, a composition comprising Bifidobacte
rium adolescentis strain BD1 and GOS is provided. In some
embodiments, the composition further includes a pharmaceu
tically acceptable carrier. Representative pharmaceutically
acceptable carrier include, without limitation, a liquid carrier,
a gel-based carrier, an oleaginous carrier, and an emulsion.
Typically, Such a composition can be in the form of a powder,
a granule, a tablet, a capsule, a liquid Suspension, a paste, and

55

FIG. 1 is graphs showing the bifidogenic effect of GOS as
determined by qRT-PCR for all eighteen subjects (A) and for
the 9 responders (B). Significance (by ANOVA) is indicated
at either p-0.05 (*) or p-0.001 (***).
FIG. 2 is graphs showing the correlation of initial bifido
bacteria levels (baseline) and the increase of bifidobacteria by
GOS feeding (from the baseline to the average of the 5 and 10
g dose levels) as measured by absolute numbers (A) and by
log increase (B).
FIG. 3 shows DDGE analysis of fecal microbiota of sub
jects 1, 2, 3 and 4 (A) and 14, 15, 16 and 17 (B) by DGGE.
Bands that were significantly affected by the GOS treatments
are outlined. Abundance scores, as measured by DGGE band

a Syrup.

intensities, from bands C, G, H, I and L, as a function of GOS

In still another aspect, a foodstuff is provided that includes
(a) an effective amount of the Substantially pure population of
bacteria or of the composition and (b) at least one food or feed
ingredient. In certain embodiments, the at least one food
ingredient is a dairy product (e.g., yogurt).
In yet another aspect, a method for establishing or main
taining a healthy gastrointestinal flora in an animal is pro
vided. Such a method typically includes administering, enter
ally, an effective amount of the Substantially pure population
of bacteria, of the composition, or of the foodstuff. Similarly,
a method for reducing the effects of a gastrointestinal disease

60

doses (C). Correlation of Bifidobacterium adolescentis band
intensities from subjects 2, 4, 14, 15 and 17 for all time points
to cell numbers, as measured by Bifidobacterium genus-spe
cific qRT-PCR (D).

45

50

Part B
FIG. 4 is a characterization of the fecal microbiota in

65

eighteen Subjects that consumed increasing doses of GOS by
multiplex pyrosequencing of 16S rDNA tags. A phylogenetic
tree that encompasses the phylum Actinobacteria is shown
(A). The tree contains representative sequences of all OTUS
detected that were significantly affected by GOS in individual

US 9,125,935 B1
3
Subjects together with sequences of related entries in the
database. The latter includes both type strains of known spe
cies and sequences from molecular studies of human fecal
samples. Sequences were aligned using Muscle 3.6 and the
trees were constructed using the neighbor-joining algorithm
with 1,000 bootstrap replicates in MEGA 4.0. The sequences
from individual Subjects are labeled using open black and
closed black symbols, and type strains and other sequenced
human strains are indicated by grey symbols. Those OTUs
that were not significantly affected in all eighteen Subjects
were labeled as “No significance'. Graphs to the right of the
trees show the abundance of the OTUs and bacterial groups
that were significantly affected by GOS. The abundances of
all of the Bifidobacterium species affected by GOS consump
tion, for all eighteen Subjects, are shown in B. These graphs
show mean proportions of the three individual samples taken
during the treatment periods for each Subject. Baseline and
washout refer to samples taken in periods where no GOS was
consumed. Repeated measures ANOVA in combination with
a Tukey's post-hoc test were performed to indentify differ
ences between treatment and control periods, where
*=p-0.05, **=p<0.01, and ***=p-0.001. Baseline and wash
out periods were not included in the statistic analysis.
FIG. 5 is a bubble plots showing differences in the propor
tions of bacterial taxa as a percentage of the entire bacteria
population detected during consumption of 5.0 g (A) and 10.0
g (B) when compared to the control period. The size of the
bubbles is representative of the percent difference. Black
ovals represent increases in proportions observed during the
GOS consumption period; white ovals represent decreases.
FIG. 6 shows the temporal dynamics of the human fecal
microbiota in response to the consumption of increasing
doses of GOS shown in five human subjects. Graphs on the
left show proportions of the three main phyla (Actinobacteria,
Firmicutes, and Bacteroidetes) and two genera (Bifidobacte
rium and Bacteroides) that were affected in subjects consid
ered as “responders'. Graphs on the right show proportions of
the same three phyla and two genera for Subjects considered
as “non-responders'.

4
Part C

10

15

DETAILED DESCRIPTION

25

30

35

40

45

50
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The present disclosure provides methods of selecting and
isolating one or more microbial strains that are naturally
occurring in the gastrointestinal microbiota and that exhibit
improved characteristics in the presence of a prebiotic. Fol
lowing isolation and characterization, the in vivo-Selected
microbial strain can be used as a probiotic and, along with the
prebiotic, can be administered as a Synbiotic composition to
an animal. For purposes herein, gastrointestinal microbiota
refers to the microbial population that is present in the gas
trointestinal tract of a Subject. The gastrointestinal tract typi
cally includes the mouth, esophagus, stomach, Small intes
tine, large intestine, rectum and anus.
As described herein, methods are provided in which a
microbial strain that is naturally present in the gastrointestinal
microbiota of one or more subjects can be specifically
selected for based on its positive response to the presence of
a prebiotic. Such methods typically start with the administra
tion of a prebiotic to a subject. As used herein, a Subject can
refer to a human or a non-human. Representative non-human
Subjects include, without limitation, livestock (e.g., Swine,
cow, horse, goat, and sheep), poultry (e.g., fowls such as
chicken and turkey), and companion animals (e.g., pets Such
as dogs and cats).
Prebiotics are defined in the art as an “ingredient that
allows specific changes, both in the composition and/or activ
ity in the gastrointestinal microbiota that confers benefits
upon host well-being and health' (see, for example, Rober
froid, 1998, Br. J. Nutr., 80:S197-202). Well characterized
prebiotics include, for example, galacto-oligosaccharide
(GOS), fructooligosaccharide (FOS), and inulin. GOS and
FOS refer to a group of oligomeric, non-digestible carbohy
drates that are produced from lactose using beta-galactosi
dases to catalyze transgalactosylation reactions. These beta
linked glycosides are recalcitrant to digestion by host
secreted enzymes in the Small intestine. Such that they reach
the colon intact and are available to the colonic microbiota. It

60

would be understood by those skilled in the art that other
compounds that fall within the definition of a prebiotic also
can be used in the methods described herein.

standard deviations for each of the strains are shown, with

GOS-grown cultures in shaded bars and control cultures in
open bars. Significant differences were determined by stu
dents T-test and indicated by asterisks, where p-0.05.

GOS, lactose, and basal MRS medium without added carbo

hydrates.
FIG. 10 is a representation of the timeline for stool and
urine collection.

FIG. 7 describes the characterization of the fecal micro

biota in eighteen Subjects that consumed increasing doses of
GOS by multiplex pyrosequencing of 16S rDNA tags. Phy
logenetic trees that encompass the phyla, Firmicutes (A) and
Bacteroidetes (B) are shown. The trees contain representative
sequences of all OTUs that were significantly affected by
GOS in individual subjects together with sequences of related
entries in the database (which included both type strains of
known species and sequences from molecular studies of
human fecal samples). Sequences were aligned in Muscle 3.6
and the trees were built using the neighbor joining algorithm
with 1,000 bootstrap replicates in MEGA 4.0. Open black,
closed black, and grey symbols were used to label sequences
from individual subjects. OTUs that were not significantly
affected in any of the eighteen subjects were labeled as “NS'.
Arrows to the right of each cluster indicate the number of
subjects that showed statistical significance after ANOVA
analysis. The direction of the arrow indicates either a signifi
cant increase () or significant decrease () for each subject
showing significance for that particular OTU cluster.
FIG. 8 shows that twenty-two anaerobic bacteria of human
gastrointestinal origin were screened in vitro to determine
their ability to utilize GOS. Average optical densities and

FIG. 9 shows the characterization of the Bifidobacterium
biota in fecal samples from a human Subject consuming GOS
and in vitro GOS fermentation of a subsequently isolated
Bifidobacterium strain. (A) Proportion of bifidobacteria in the
fecal microbiota as determined by pyrosequencing. Chews
with four increasing doses (0, 2.5, 5, and 10 g) of GOS were
consumed in Succession, each for three weeks. Analyses of
fecal samples collected weekly are shown. (B) Proportion of
Bifidobacterium lineage spp. II in the same fecal microbiota
as determined by pyrosequencing. (C) Total numbers of bifi
dobacteria in the same fecal samples as determined by qRT
PCR. (D) Growth of Bifidobacterium adolescentis BD1 on

65

Typically, a subject is administered (e.g., asked to ingest) at
least one dose of the prebiotic but, more often, a number of
doses overa period of time (e.g., one or more doses per day for
multiple days (e.g., for about or at least a week, for about or at
least two weeks)). In some instances, to help or further vali
date the correlation between an increase in a microbial strain

US 9,125,935 B1
6
versity Blvd., Manassas, Va. 20110) on Oct. 8, 2013, and
assigned Accession No. PTA-120614.

5
and the presence of a prebiotic, the Subject can be adminis
tered (e.g., asked to ingest) a prebiotic in sequentially higher

The B. adolescentis BD1 strain or other strains identified

doses over time.

At selected points while the Subject is ingesting the prebi
otic, Samples that contain gastrointestinal microbiota are col
lected from the Subject. In most instances, the sample is a
fecal sample, but other samples, provided they contain gas
trointestinal microbiota, are suitable for use in the methods

described herein (e.g., an enema wash, a sample taken during
a colonoscopy). It would be understood by those skilled in the
art that, for comparison purposes, at least one baseline sample
needs to be obtained from each subject. As used herein, a
baseline sample refers to a sample that is taken or obtained
from the subject before any prebiotic is ingested or following
a sufficient time period after the prebiotics are no longer
ingested. Obviously, multiple baseline samples can be
obtained from the same subject.
Of particular interest are the microbial strains that increase
in the presence of the prebiotic compared to, for example, one
or more baseline samples. Standard laboratory methodolo
gies are routinely used to identify the genera that are present
in the gastrointestinal microbiota. These methods can include
gram staining, differential culture conditions (e.g., utilizing
different culture media under aerobicfanaerobic conditions at

10

Media for Food Microbiology, 2" Ed., Vol 37, Corry et al.,

eds., 2003, Elsevier Science. In addition, there is a commer
15
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different, temperatures), immunological assays, and/or
MALDI-TOF. In addition, routine laboratory methodologies
can be used to isolate one or more microbial strains that are

increased in a Subject in the presence of the prebiotic. As used
herein, “isolated’ refers to a population of microbial cells in
which at least about 80% (e.g., about 85%, 90%, 95%,99% or
100%) of the cells are the B. adolescentis BD1 strain
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In some embodiments, the microbial strain and the prebi
otic (e.g., the Synbiotic) can be contained within a foodstuff.
Foodstuffs include any number of food products that are
Suitable for human consumption Such as, without limitation,
milk, yogurt, juices, water, cereals, chewing gum, crackers,
candies, cookies, vitamin Supplements, meats, and fruits or
Vegetables (i.e., blended fruits or vegetables Such as, e.g.,
baby food). Foodstuffs also include feed products (e.g., suit
able for consumption by livestock or companion animals)
including dry animal feeds. In certain embodiments, the B.
adolescentis microbial strain described herein along with
GOS can be mixed into liquid feed or drinking water, or
combined with a carrier and applied to solid feed.
A composition or a foodstuff that includes the microbial
strain (e.g., B. adolescentis BD1) and the prebiotic (e.g.,
GOS) as described herein can include a pharmaceutically
acceptable carrier. A pharmaceutically acceptable carrier
should be non-toxic to the bacteria and to the animal, and also

50

be identified, based on in vivo selection, that increases in

number or otherwise responds positively to the presence of a
prebiotic. In addition to an increase in number of one or more
microbial strains in the presence of a prebiotic relative to a
baseline sample, a "positive response' can refer to, for
example, an increase in metabolic activity by the microbial
strain (i.e., in the absence of an increase in number) or both an
increase in number and an increase in metabolic activity.
As described herein, this method has been used to identify
a microbial strain that responds particularly well in a number
of subjects to the prebiotic, GOS. This microbial strain was
identified as a Bifidobacterium adolescentis strain, and was
assigned the designation BD1. This strain was deposited with
the American Type Culture Collection (ATCC, 10801 Uni

cially available selective medium defined specifically for cul
turing Bifidobacterium (e.g., BD Bifidobacterium Agar from
Becton, Dickinson & Co.).
After selecting, identifying and isolating a microbial strain
using the methods disclosed herein, and after confirming the
microbial strains affinity for the prebiotic, the microbial strain
can be administered to an animal (e.g., as a probiotic). Given
the method by which the microbial strain was obtained, it is
preferred that the microbial strain be administered to an ani
mal in conjunction with the corresponding prebiotic. In some
embodiments, the microbial strain and the prebiotic are com
bined prior to administration to produce a symbiotic. Typi
cally, the animal that is administered the rationally-designed
synbiotic is of the same species as the subject from which the
microbial strain originally was identified. As described above
with respect to the Subjects, the animal can be a human or any
number of non-human animals.

30

described herein.

In some instances, following the culture methods of iden
tification, one or more methods of genotyping can be used to
further confirm the genus and/or genus and species of one or
more microbial strains. Because they are extremely highly
conserved, the genes encoding the rRNA sequences (rDNA)
are routinely used to determine taxonomy as well as phylog
eny and rate of divergence. For example, PCR with restriction
fragment length polymorphism (RFLP) of the 16S rDNA can
be used to genotype microorganisms (see, for example,
Urakawa et al., 1997, FEMS Microbiol. Lett., 152:125-32),
sequencing of the 16S rRNA can be used to genotype micro
organisms (see, for example, Weisburg et al., 1991, J. Bacte
riol., 173:697-703), or mass spectroscopy of cleaved 16S
rDNA or rRNA can be used to genotype microorganisms (see,
for example, Jackson et al., 2006, BMC Bioinformatics,
7:321). These methods are routinely used in microbiology
and are continually being modified and improved upon; the
methods described herein are not to be limited by any par
ticular methods used to genotype microorganisms.
Using the methods described herein, a microbial strain can

using the methods herein can be provided as a Substantially
pure population. As used herein, a “substantially pure popu
lation of cells means that at least about 50% (e.g., about
55%, 60%. 65%, 70%, 75%, 80% or greater) of the cells
present are the B. adolescentis BD1 strain described herein.
Methods of culturing B. adolescentis are well known to those
of skill in the art. See, for example, Handbook of Culture
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can include an ingredient that promotes viability of the micro
organism during storage. Liquid or gel-based carriers are well
known in the art, such as water, fruit juice, glucose or fructose
Solutions, physiological electrolyte solutions, and glycols
Such as methanol, ethanol, propanol, butanol, ethylene glycol
and propylene glycol. Carriers also include oleaginous carries
Such as, for example, white petrolatum, isopropyl myristate,
lanolin or lanolin alcohols, mineral oil, fragrant or essential
oil, nasturtium extract oil, Sorbitan mono-oleate, cetylstearyl
alcohol, hydroxypropyl cellulose (MW=100,000 to 1,000,
000), or detergents (e.g., polyoxyl Stearate or sodium lauryl
sulfate). Other suitable carriers include water-in-oil or oil-in
water emulsions and mixtures of emulsifiers and emollients
are provided.
A composition or a foodstuff that includes the microbial
strain (e.g., B. adolescentis BD1) and the prebiotic (e.g.,
GOS) as described herein also can include natural or syn
thetic flavorings and food-quality coloring agents, thickening
agents such as corn starch, guar gum, Xanthan gum and the
like, binders, disintegrators, coating agents, lubricants, stabi

US 9,125,935 B1
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lizers, Solubilizing agents, Suspending agents, excipients, and
diluents. Additional components also can be included that, for
example, improve palatability, improve shelf-life, and impart
nutritional benefits. It would be understood by those in the art
that any additional components in a composition must be
compatible with maintaining the viability of the microbial

5

strain.

Administration of a composition or a foodstuff that
includes the microbial strain (e.g., B. adolescentis BD1) and
the prebiotic (e.g., GOS) as described herein can be accom
plished by any method that delivers at least a portion of the
microorganisms and prebiotic into the digestive tract of an
animal. Therefore, enteral administration is preferred (e.g.,
orally, Sublingually, or rectally), although other routes are not
excluded. Generally, the formulation of a composition is
dependent upon its intended route of delivery. For example, a
composition that includes the B. adolescentis BD1 strain
(with or without GOS) as described herein can be formulated
as a powder, a granule, a tablet, a capsule, a liquid Suspension,

10

related metabolic disorders.

In some embodiments, the microbial strain described
15

a paste, or a Syrup.

An effective amount of the microbial strain (i.e., a probi
otic) described herein is an amount that achieves a desired
result (e.g., treatment or maintenance) in the absence of a
toxic, immunological, or allergic reaction in the animal. An

effective amount can be at least 10" viable colony forming
units perday (CFU/day; e.g., at least 10 CFU/day, 10 to 10'’
CFU/day, or 10' CFU/day), which can be administered in a

single dose or over multiple doses (e.g., over days, weeks,
months or years). When the microbial strain described herein
is administered over a long period of time (e.g., to maintain a
healthy gastrointestinal flora), the effective amount may be

25

Bifidobacteria strain described herein can be administered in

constipation, loose stool, abdominal inflation, ulcerous coli

johnsonii, Lactobacillus farcininus, Lactobacillus gasseri,
Lactobacillus helveticus, Lactobacillus rhamnosus, Lactoba
cillus sake, Lactococcus lactis, Micrococcus varians, Pedio

day). It would be understood by those in the art that the

trointestinal diseases include, without limitation, diarrhea,

herein, with or without a prebiotic, can be administered with
one or more additional probiotic microbial strains. Examples
of additional probiotic microorganisms that can be used
include yeasts Such as Saccharomyces, Candida, Pichia and
Torulopsis, moulds Such as Aspergillus, Rhizopus, Mucor,
and Penicillium and bacteria Such as the genera Lactobacil
lus, Bifidobacterium, Clostridium, Leuconostoc, Bacteroi
des, Staphylococcus, Lactococcus, Bacillus, Streptococcus,
Fusobacterium, Propionibacterium, Enterococcus, Pedio
coccus, and Micrococcus. Representative examples of addi
tional probiotic microorganisms that can be used include
Saccharomyces cereviseae, Bacillus coagulans, Bacillus
licheniformis, Bacillus subtilis, Bifidobacterium bifidum,
Bifidobacterium infantis, Bifidobacterium longum, Entero
coccus faecium, Enterococcus faecalis, Lactobacillus acido
philus, Lactobacillus alimentarius, Lactobacillus casei, Lac
tobacillus curvatus, Lactobacillus delbruckii, Lactobacillus

30

less than the foregoing range (e.g., 10 CFU/day to 10 CFU/

an amount that exceeds the foregoing range as many Bifido
bacteria strains are considered to be highly safe and have been
given GRAS (Generally Recognized As Safe) status by the
U.S. Food and Drug Administration (FDA). It would be
appreciated by those skilled in the art that, in the presence of
the prebiotic, the effective amount (i.e., the amount that
achieves a desired result) may be reduced and/or the thera
peutic effect may be increased with the same or less amount.
Probiotics are reported to produce health benefits which
include (1) alleviation of intestinal disorders such as consti
pation and diarrhea caused by infection by pathogenic organ
isms, antibiotics, or chemotherapy; (2) stimulation and
modulation of the immune system; (3) anti-tumor effects due
to inactivation or inhibition of carcinogenic compounds in the
gastrointestinal tract by reduction of intestinal bacterial
enzyme activities such as beta-glucuronidase, azoreductase,
and nitroreductase; (4) reduced production of toxic end prod
ucts Such as ammonia, phenols and other metabolites of pro
tein known to influence liver cirrhosis (5) reduction in serum
cholesterol and blood pressure; (6) maintenance of mucosal
integrity; (7) alleviation of symptoms of lactose intolerance;
(8) prevention of vaginitis. Accordingly, the beneficial effects
attributed to probiotics include increased resistance to infec
tious diseases, healthier immune systems, reduction in irri
table bowel syndrome, reductions in blood pressure, reduced
serum cholesterol, milder allergies and tumor regression. In
animals, for example, probiotics can enhance weight gain or
weight loss and improve meat quality, and milk production.
Significantly, probiotics can be used to establish and maintain
a healthy (e.g., balanced) gastrointestinal flora in an animal
and to reduce the effect of gastrointestinal diseases. Gas

8
tis, Crohn's disease, irritable bowel syndrome, hypersensitive
intestinal syndromes, food toxicity, food allergy,
pseudomembranous colitis, hemorrhagic colitis, gastritis,
gastroduodenal ulcer, dental caries, and periodontitis. See, for
example, Vaughan, Gastrointestinal Microbiology, 2006,
CRC Press. Specifically, Bifidobacteria may prevent or
reduce the effects of metabolic disorders such as obesity and
type 2 diabetes by reducing gut permeability. Reducing gut
permeability can improve metabolic endotoxemia and meta
bolic inflammation, both of which are involved in obesity and
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coccus acidilactici, and Staphylococcus xylosus.
The microbial strain described herein can be provided in an
article of manufacture (e.g., in lyophilized form), with or
without a prebiotic. An article of manufacture also can
include one or more pharmaceutically acceptable carriers
(e.g., a solvent), and further can include one or more tools for
combining and mixing the microorganism with the prebiotic
and/or the pharmaceutically acceptable carrier or administer
ing the composition (e.g., a stick or a straw). In addition, an
article of manufacture can include one or more other probiotic
microorganisms. An article of manufacture also can include
appropriate packaging material, and may include written
directions or instructions for use (e.g., dosage information) or
for administration.

50

In accordance with the present invention, there may be
employed conventional molecular biology, microbiology,
biochemical, and recombinant DNA techniques within the
skill of the art. Such techniques are explained fully in the
literature. The invention will be further described in the fol

lowing examples, which do not limit the scope of the methods
and compositions of matter described in the claims.
55

EXAMPLES
Part A

Example 1
60

Preparation of Chocolate Chews

65

Chocolate-flavored chewable candies (chews) containing
GOS and control chews (with no GOS) were prepared at the
University of Nebraska-Lincoln Food Processing Center. The
GOS used was PurimuneTM, a high purity GOS powder
(91.8% on a dry basis) provided by GTC Nutrition (Golden,

US 9,125,935 B1
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Colo.). The balance of the GOS contained lactose (7%), glu
cose (<1%), and galactose (<0.5%). The chocolate chews
were formulated to contain 1.25 g of GOS per 6 g chew.
Additional corn syrup and Sucrose were included in the con
trol chews containing no GOS. The formulations of both the

10
provided as part of weekly subject diaries. The study was
approved by the Institutional Review Board of the University
of Nebraska.

Example 3

GOS and control chew are shown in Table 1. Chews were

wrapped individually in wax paper and stored in sealed plas
tic bags at 20°C. The chews were distributed to subjects on a
weekly basis.

Collection and Processing of Fecal Samples
10

TABLE 1.
Control chocolate

GOS chocolate

chew

chew

Water

1162

11.54

Sugar

27.35

1942

GOS (Purimune)
Corn syrup

O.OO
44.84

23.40
31.83

Palm Kernel oil

7.62

541

Chocolate liquor

7.58

7:44

0.55
0.44

O.S3
O43

Ingredient

15

(1/2 bakers)
Lecithin
Vanilla

Example 2

25

Experimental Design
The study included 21 healthy human volunteer subjects
that were recruited on the University of Nebraska-Lincoln
campus. None of the Subjects had been on antibiotics or on a
vegetarian diet within three months prior to the start of the
study or during the study. Subjects were allowed to maintain
their normal lifestyles without any additional restrictions on
their diets. Two subjects dropped out of the study for reasons
unrelated to the experiment and one subject was released
from the study due to pregnancy. Thus, a total of eighteen
subjects, 13 males and 5 females, between the ages of 19 and
50 years old, completed the study. The study was conducted
over a 16 week period. A two-week baseline period (no chews
administered) was conducted at the beginning of the study,
followed by four sequential testing periods during which
chews were administered for three weeks with GOS dosages
at levels of 0.0g, 2.5 g. 5.0 g, and 10.0 g GOS per day.
Subjects were blinded in terms of the dose of GOS they
received, and instructed to consume eight chews per day
during each testing period, with the only difference being the
number of GOS-containing chews included in the daily regi

30
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were also used to plate aliquots aerobically on MacConkey
Agar (BD) for enterobacteria (24 h), and Bile Esculin Azide
Agar (Acumedia, USA) for enterococci (48 h). Plates were
incubated aerobically at 37°C. These organisms were chosen
for cultural enumeration based on previous prebiotic and
probiotic feeding studies (Tannock et al., 2000, Appl. Envi
ron. Microbio., 66:2578-88; Tannocket al., 2004, Appl. Envi
ron. Microbio., 70:2129-36).
The fecal pH was measured in aqueous slurries using an
Ag/AgCl pH meter (Accumet Basic AB15 pH meter, Fisher
Scientific). Statistical analysis was completed using a one
way ANOVA as well as Tukey's post-hoc pair-wise compari
Example 4
DNA Extraction

45

50

55

A 1 mL aliquot of a 1:10 diluted fecal sample in PBS was
transferred to sterile bead beating tubes (Biospec products,
Bartlesville, Okla.) containing 300 mg of zirconium beads
(0.1 mm). Fecal cells were washed three times in chilled PBS
using centrifugation at 6,000xg for 5 min. Pellets were resus
pended in 100 uLoflysis buffer (200mMNaCl, 100mM Tris,
20 mM EDTA, 20 mg/mL Lysozyme, pH 8.0) and incubated
at 37° C. for 30 min. Buffer ASL (1.6 mL) from the QIAamp
DNA Stool Mini Kit (Qiagen, Hilden, Germany) was added
to each sample after the samples were homogenized in a
MiniBeadbeater-8 (BioSpec Products, OK, USA) for two
min at maximum speed. The DNA was purified from the
supernatants using the QIAamp DNA Stool Mini Kit, follow
ing the Qiagen kit manufacturers instructions.
Example 5

60

Quantitative RealTime-PCR

Am. J. Clin. Nutr., 69:980-91; Bouhnik et al., 2004, Am. J.
Clin. Nutr, 8.0:1658-64; and Shadid et al., 2007, Am. J. Clin.

Nutr., 86:1426-37) and included bowel movement, stool con
sistency, discomfort, flatulence, abdominal pain, and bloat
ing, and were scored on a one (none, normal, good well
being) to five (severe symptoms and discomfort) scale

that were used to enumerate bifidobacteria were also exam
ined at 48 h to estimate lactobacili levels. Serial dilutions

SOn test.

men, which could not be differentiated from control chews.

Thus, during the control period, 8 control chews were con
sumed, and during the 2.5 g treatment period, 2 GOS chews
(each containing 1.25 g GOS) and 6 control chews were
consumed. The 5 g treatment period included 4 GOS and 4
control chews and the 10 g treatment consisted of 8 GOS
chews. A final two-week washout period (no chews) was
performed at the end of the fourth testing period. All of the
dosages were sequential with no washout periods between
dosages. Subjects were asked to report the presence, absence,
and severity of gastrointestinal symptoms experienced
throughout each week of the study. The symptoms Survey was
based on previously reported studies (Bouhnik et al., 1997,

Fecal samples were collected weekly from each subject.
Each sample was processed within 1 hour of a bowel move
ment. All fecal samples (1.0 g) were weighed and diluted
10-fold with sterile phosphate buffered saline (PBS; pH 7.0).
Samples were homogenized and immediately frozen at -80°
C. and saved for DNA extraction. Fecal samples (1.0 g) were
also immediately introduced into an anaerobic chamber (Bac
tron IV Anaerobic Chamber. Shel Lab, Cornelius, Oreg.) and
a 10-fold dilution series was made with pre-reduced sterile
saline (0.9% NaCl). Aliquots were plated on Brain Heart
Infusion Agar (Becton Dickinson; BD, Franklin Lakes, N.J.)
for total anaerobes (incubated 48 h), Rogosa SL (BD) for
Bifidobacterium (96 h), and Bacteroides Bile Esculine Agar
(BD) for Bacteroides (48 h). All plates were incubated
anaerobically at 37°C. In addition, the Rogosa SL agar plates

65

Quantitative real time PCR (qRT-PCR) was performed as
previously described (Martinez et al., 2009, Appl. Environ.
Microbiol., 75:4175-84) using a Mastercycler Realplex 2 (Ep
pendorf AG, Hamburg, Germany) with Bifidobacterium-spe
cific primers F: 5'TCG CGT C(C/T)G GTG. TGA AAG3

US 9,125,935 B1
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(SEQ ID NO:1) and R: 5'CCA CAT CCA GC(A/G) TCC
AC3 (SEQID NO:2: Martinez et al., 2009, supra; Rinttila et
al., 2004, J. Appl. Microbiol., 97:1166-77), with an amplicon
size of 243 bp. Standard curves for absolute quantification of
bifidobacteria in the fecal samples were prepared using OVer
night cultures (14 h) of Bifidobacterium animalis ATCC

12
Example 7

5

25527T and Bifidobacterium infantis ATCC 15697T. For

Statistical Analysis
One-way ANOVA tests with repeated measures were used
to determine significance between the different doses of GOS
(0, 2.5 g., 5 g, and 10 g) and the control. Baseline/washout

samples were combined for the analysis and referred to as

each qRT-PCR experiment, a standard curve was prepared, in

“none'. Statistical analysis was performed for the combined

duplicate, using DNA extracted from cultures at concentra-

data from the eighteen subjects and to identify statistically

tions ranging from 105-108 CFU/mL. Correlation coeffi- 10 used
significant
increases
of individual
Subjects. Tukey's test was
for post
hoc pair-wise
comparisons.
cients for all standard curves were above 0.95.

p

p

p

Example 8

Example 6

Digestive Tolerance of GOS
Analysis by PCR-DGGE
15 All eighteen Subjects completed a weekly symptoms diary
throughout the duration of the study. These symptoms diaries
PCR-DGGE was performed as described (Martinez et al., allowed Subjects to rate bowel movement, stool consistency,
2009, Supra). Briefly, the V3 region of the 16S rRNA gene was discomfort, flatulence, abdominal pain, and bloating on a
amplified by PCR using universal primers PRBA338fGC scale of one (none, normal, good well-being) to five (severe
(5'CGC CCGCCGCGC GCG GCG GGC GGG GCGGGG symptoms and discomfort). Based on a one-way ANOVA of
GCA CGG GGG GAC TCC TAC GGG AGG CAG CAG3;
the data, no significant differences were detected for any of

SEQID NO:3) and PRUN518r (5'ATT ACC GCGGCTGCT

the symptoms between the 00 g GOS control dose and any of

GG'3: SEQ ID NO:4) (Ovreas et al., 1997, Appl. Environ.
the GOS treatments (Table 2). A significant symptom change
was observed for flatulence (p<0.05), but only between the
Microbio., 63:33.67-73). Denaturing Gradient Gel Electo- 25 baseline and washout and the treatment periods. However, the
phoresis (DGGE) was performed aS described previously increase in this score occurred not only for the GOS treat
(Walter et al., 2000, Appl. Environ. Microbio., 66:297-303), ments, but even during consumption of the 0.0 g GOS control
using a DCode universal mutation detection system (Bio- period.
TABLE 2

Mean it standard deviations of weekly symptoms.

Reported on a scale of 1 (best) to 5 (worst
Baseline
Bowel movement
Stool consistency
Discomfort
Flatulence
Abdominal pain
Bloating

1.42O55
1560.64
142 O.69
1520.78
1.17 O.38
1.14 - 0.33

0.0g
157
1.63 148
1.83 131
1.39

0.61
0.68
0.60
0.75*
O.49
O.75

2.5g
144
1.54 1.56 1.85
1.33
1.43

OSS
0.68
O.S7
0.79*
O40
O.47

5.0 g

10.0 g

Washout

1.390.51
1.54 - 0.73
144 - O.65
1.86 0.75*
130 OSO
130 O.65

146 - 0.61
1.57 0.65
1.520.73
2.07 - 0.88:
1.30 - 0.60
148 - 0.90

142 (0.79
1.50 - 0.84
1.14 - 0.38
1.25 O.S.S
1.14 - 0.41
1.080.26

*Significant differences detected by ANOVA (p<0.05) between the GOS and baseline and washout treatments.
Tukey's post-hoc test did not detect significant differences in pair-wise comparisons,

Rad, Hercules). Band fragments of interest were excised,

Example 9

repeatedly purified (Walteret al., 2001, Appl. Environ. Micro- as
bio., 67:2578-85), and then cloned using the TOPORTA
Cloning R. Kit for Sequencing (pCRR 4TOPOR, Vector) (In-

Cultural enumerations were performed for total anaerobic
bacteria and for lactose-fermenting enterobacteria, entero

vitrogen). The QlAprep Spin Miniprep Kit (Qiagen, Hilden,

cocci, Bifidobacterium, and Bacteroides. Lactobacili counts

Germany) was used to isolate plasmids from transformants,

and inserts were sequenced by a commercial provider. Clos- 50

est relatives of the partial 16S rRNA sequences were deter-

mined using the SeqMatch web tool provided through the
Ribosomal Database Project (rdp.cme.msu.edu on the World
Wide Web).
BioNumerics software Version 5.0 (Applied Maths) was

used to analyze DGGE profiles. DGGE bands were automati-

cally assigned
and densitometric curves were obtained based
- - -

Fecal Bacteria Counts
were very low (<106/g) throughout the entire duration of the
study, even during treatment periods. When the data for each
individual
subject was analyzed, the results revealed that for
Some Subjects, statistically significant differences in several

of these groups were observed following consumption of
GOS. When the results of all eighteen subjects were pooled

55

together, no significant changes were detected for levels of
Bacteroides, enterococci, or lactose fermenting enterobacte
ria. However, ANOVA revealed that GOS induced a modest,

but statistically significant increase of bifidobacteria com

pared
to the control treatment (Table 3). This bifidogenic
effect occurred when subjects had consumed the 5 g dose of

on the staining intensity profiles generated by the BioNumer- GOS, and a further increase in dose to 10 g of GOS was not
ics Software. Band staining intensities were calculated as a 60 significant when compared to the 5g dose. In contrast, how
percent of each peak area of the entire fingerprint generated ever, the 10g dose did result in a significant increase in total
for the individual sample. The reliability of this quantification anaerobes compared to the 2.5g dose. In addition, the bacte
method was previously determined by comparing taxa abun- rial populations that was observed for all groups were similar
during the baseline and washout periods.
dance inferred by DGGE band intensities with those obtained
The pHs of all of the fecal samples (288) were determined.

with pyrosequencing of 16S rRNA tags in studies on the 65 All but two of the samples had pH values between 60 and 8.0,

hamster microbiota, and received correlations of ro-0.8 (Martinez et al., 2009, supra).

and there were no significant treatment differences in pH
observed over the period of the study.

US 9,125,935 B1
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TABLE 3

Enumeration of bacterial groups through culturing
Log 10 CFU/g feces (meant SD
Bacterial Group
Lactose fermenting
Enterobacteria
Enterococci
Bifidobacteria
Bacteroides
Total anaerobes

Baseline
560 - 1.14
5.02
9.32
9.S6
10.19

O.Og
568

2.5g

1.07

5.0 g

S.64 - 0.86

0.99 SO2 - 1.07 4.95 0.79 9.48 O.73 96.O.
0.37 9.58 0.37 9.59
O.28, 10.19 O.2O 10.11 -

0.99
O.80
0.35
0.23

10.0 g

5.18

126

4.67 +
9.76
947
10.24

O.93
O.48*
0.32
O.15

S.S9

Washout

O.85

5.78

4.70 - 0.90
9.83 - 0.56***
9.53 0.35

1.17

5.13 - 1.10
9.42 - O.S2
9.53 0.33

10.35 + 0.16** SSS 10.19 + 0.21

Significantly difference to 0.0g: * (p < 0.05), **(p<0.01), **(p<0.001).
Significantly difference to 2.5g: SSS(p<0.001).
15

Example 10

was a responder or non-responder. In contrast, the baseline
cell count of bifidobacteria in subjects was a major determi
nant for the bifidogenic effect when this effect was based on

Genus Specific qRT-PCR for Enumeration of

the difference in actual numbers from the baseline to the

Bifidobacteria

average of the 5 and 10g treatments. As shown in FIG. 2A,
initial levels of bifidobacteria directly correlated with the
increase of bifidobacteria numbers. However, the bifidogenic
effect, expressed as the "log increase', was inversely corre
lated with the initial bifidobacteria levels (FIG. 2B). In other
words, subjects with low numbers of bifidobacteria had a
higher potential for the prebiotic to induce a 100-1000 fold
increase, while Subjects that already possessed high levels of
bifidobacteria were able to achieve an even higher increase in

2O

The culture analysis indicated that a bifidogenic effect
occurred due to consumption of GOS, and that this effect was
detectable at doses of 5 g and 10g, with no significant differ
ences between the two high doses. In order to confirm these
findings without a potential cultivation bias, cell numbers of
bifidobacteria in fecal samples were quantified by genus
specific qRT-PCR. As shown in FIG. 1A, the Bifidobacterium
population in the eighteen subjects increased with the inclu
sion of chews containing different amounts of GOS. As

25

before for cultural enumeration, this increase reached statis

30

tical significance when 5g and 10 g of GOS were consumed
(p<0.001). The analysis also showed major differences in the
dose response relationships in individual Subjects. In total,
Bifidobacterium numbers were significantly increased by
GOS consumption in nine of the eighteen subjects as ana
lyzed by ANOVA. FIG. 1B shows the numbers of bifidobac
teria in these nine “responders’. This data showed an equiva
lent gradual increase of bifidobacteria with dose, with no
significant differences between 5 and 10 g of GOS.
To determine if the baseline Bifidobacterium population
influenced the prebiotic effect, the initial bifidobacteria levels
was compared between responders and non-responders. The
Student's t test did not reveal any significant differences
between these groups, indicating that initial number of bifi
dobacteria did not determine whether any specific individual

absolute numbers.

Example 11

Characterization of Total Fecal Bacterial Populations
by PCR-DGGE
To obtain abroader assessment of the impact of GOS on the
fecal microbiota, a universal PCR-DGGE approach was used
to determine the dynamics of the community fingerprints.
These analyses revealed a high level of stability among the
gut microbiota in all of the subjects. The DGGE gels corre
sponding to the eight Subjects with the most pronounced
changes in staining intensities upon consumption of GOS are
shown in FIG. 3. Quantification of DGGE band intensities
was then performed using BioNumerics Software, as previ
ously reported (Martinez et al., 2009, Supra), revealing sev
eral major effects (Table 4).
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TABLE 4

Ratio of staining intensities of major bands as proportion of total fingerprint intensity (%).
Mean band intensity (SD)
DGGE

Subject fragment

Baseline

0.0 g

2.5g

5.0 g

10.0 g

Washout

Increasing significance
4

2

C
F
G

3.68 O.O2 2.76
3.13 - O.O2 1.23
1.46 OOO7 3.94

14
15

H
I

3.41. O.16
O.OOOOO

17

L

O.92 OOO2 1.73

O.OO9 4.87 OO1
O.OO1 383 + O.O2
O.O2 2.7OOOO4

6.40 OO6 8.57
O.OOOOO 148

O.O2
O.OO2

O.O1 148 OO1

6.67 + O.O3
O.OOS
5.51 O.O1

11.89 + 0.04**s
6.96 O.O2**
9.75 + 0.03*ss

2.93 + O.O2
1.39 O.OO2
1.21 O.OO3

741 - 0.008
2.53 0.01.**

8.06 O.O2
2.55 + 0.002**

O.69 O.O1
OOOOOO

3.33

5.150.007

10.00 + 0.03***ssst

0.60 + 0.002

Decreasing significance
1
3

A.
B
D

11.91 O.O3 10.73
5.07 - O.O1 350
6.51 O.O2
7.06

O.O3 2.79 O.O.S*
OO1 3.17 O.O1
O.O3
42 0.04

O.12 O.OO1** O.19
2.88 O.OO3
1.03
130 O.O2
O.OO1

O.OO2**
OOO2
O.OO2

1.15
2.51
4.50

O.O1
O.O1
O.OO4

US 9,125,935 B1
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TABLE 4-continued

Ratio of staining intensities of major bands as proportion of total fingerprint intensity (%).
Mean band intensity (tSD
DGGE

Subject fragment

Baseline

O.Og

4

E

1.88 O.OO1

16
17

J
K

9.74 O.O3 8.OOOO3 7.15
8.70 - O.OO2 3.68 0.04 6.79

2.5g

1.66 OOOS 3.35 - O.OO3
O.OO9
O.O2

5.0 g

10.0 g

Washout

2.69 O.O2

0.35 + 0.0009S

2.63

4.13
2.80

4.1OOOOS
O.63 OOOS

4.33 O.OO4
2.83 - 0.004

O6
O.O2

O.O2

Significantly different to 0.0g: *(p<0.05), **(p<0.01), ***(p<0.001).
Significantly different to 2.5g: S(p<0.05), SS(p<0.01), SSS(p<0.001).
Significantly different to 5.0 g (p<0.05).
Subjects 3, 14, 2B, 16, 17K are included because they are approaching significance (p<0.05) at 10g compared to 0.0g,

The most consistent alteration in band staining intensity
resulting from consumption of GOS was a band at the bottom
of the DGGE gels (labeled as C, G, H, I, and L), that was
present in five subjects, 2, 4, 14, 15, and 17 (FIGS. 3A and
3B). Excision of the band and subsequent purification and
DNA sequencing revealed that the band corresponded to Bifi
dobacterium adolescentis (Table 5). The staining intensity of
this band clearly showed a dose dependent increase (Table 4),
although differences were observed between subjects with
respect to the effective dose (ranging from 2.5-10 g). How
ever, when the band intensity values from these five subjects
were averaged, the results revealed that a bifidogenic effect
occurred only when the GOS dose reached 10 g (FIG. 3C).

15

PLoS ONE, 5:e15046). Briefly, the V1-V3 region of the 16S
rDNA gene was amplified by PCR from fecal DNA using
primers adapted for the Roche-454 Titanium kit. A mixture
(4:1) of the primers B-8FM: (5'-CCT ATC CCC TGT GTG
CCTTGG CAGTCT CAGAGA GTTTGATCMTGG CTC

AG-3'; SEQID NO:5) and B-8FMBifido: (5'-CCTATCCCC
TGT GTG CCTTGG CAG TCT CAGAGGGTT CGATTC

TGG CTCAG-3'; SEQID NO:6), were used as the forward
primers. The primer A518R: (5'-CCA TCT CAT CCCTGC
25

GTG TCTCCG ACT CAGBBBBBBBBATTACCG CGG

CTG CTGG-3'; SEQID NO:7) containing an 8-basebarcode
sequence was used as the reverse primer. Sequences were
then assigned to their respective samples via the barcode. The

TABLE 5

Subject
1
2
3
4
14
15
16

Band Closest related GenBank sequence (% similarity between DGGE
fragment fragment and GenBank sequence)
A.
B

Ruminococcus uncultured bacterium; 29A-b4; DQ905715 (99%)
Lachnospiraceae uncultured bacterium; RL197 aah88b02;

C
D
E
F
G
H
I

DQ794455 (100%)
Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%)
Bacteroides uncultured bacterium; NO48: AY916250 (100%)
Bacteroides uniformis (T); JCM 5828T; AB050110 (100%)
Bacteroides doei (T); JCM 13471; 175; AB242142 (100%)
Bifidobacterium adolescentis; E-981074T; nur-5; AF275882 (99%)
Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%)
Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%)

J

Ruminococcaceae uncultured bacterium; RL185 11 n85a.07;

K
L

Ruminococcus uncultured bacterium; B086; DQ325583 (97%)
Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%)

DQ825073 (100%)
17

Collectively, the abundance of B. adolescentis, as deter
mined by staining intensity, was remarkably quantitative and
highly correlated to cell numbers as determined by qRT-PCR
(FIG. 3D). Also, as shown in FIG.3 and Table 4, the increase

50

in B. adolescentis was reversible and returned to the baseline

level within a week of wash out. Consumption of GOS also
resulted in several other reversible alterations in the fecal

55

microbiota; however, most of these alterations related to a

decrease in staining intensity of bands that corresponded to
different colonic microorganisms (Table 5).
Part B
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Example 12
Analysis of the Fecal Microbiota by Pyrosequencing
65

Pyrosequencing of 16S rDNA tags was performed from
fecal DNA as described previously (Martinez et al., 2010,

8FMBifido was used in combination with primer 8FM, as 16S
DNA sequences within the genus Bifidobacterium are not
well amplified by the latter primer (Martinez et al., 2009,
Supra).
Equal amounts of the PCR products were combined and
gel purified and then sequenced with the 454/Roche A
sequencing primer kit using a Roche Genome Sequencer
GS-FLX. Sequences were binned according to barcodes,
using the Ribosomal Database Project (RDP) Pyrosequenc
ing Pipeline (pyro.cme.msu.edu/ on the World Wide Web)
Initial Process tool (Cole et al., 2009, Nuc. Acids Res.,
37:D141-5). Default parameters were established to remove
sequences containing any ambiguous nucleotides, except for
the minimum sequences length, which was set to 300 bp.
BioEdit Software was used to trim the quality approved
sequences to 450 bp before Submission to the sequence analy
ses (see below).

US 9,125,935 B1
17
Example 13

18
Linkage Clustering. Individual cluster files corresponding to
each fecal sample were used to construct Rarefaction curves
and determine the Shannon's Index.

Sequence Analyses to Characterize Microbial
Populations
Sequences obtained by pyrosequencing were analyzed
using taxonomy-dependent and taxonomy-independent
approaches. First, the Classifier tool of the RDP was applied
(with a minimum bootstrap value of 80%) to obtain a taxo
nomic assignment of all sequences. The Classifier approach
allowed a fast determination of the proportions of bacterial
groups at different taxonomic levels (phylum to genus). Alter
natively, the sequences were assigned to Operational Taxo
nomic Units (OTUs). Accordingly, all sequences from each
subject were individually aligned using the RDP Aligner web
tool, and then clustered using the RDP Complete Linkage
Clustering web tool (with a maximum distance cutoff of 97%;
Cole et al., 2009, supra). The OTU picking was performed on
a per subject basis, as the entire data set from all of the
Subjects contained too many sequences for a quality align
ment. OTUs that contained less than three sequences were
excluded from the analyses. Using Statistical Analysis Soft
ware (SAS) to perform ANOVA, the OTUs that were signifi
cantly affected by the treatments in each subject were identi
fied.

Example 15
Statistical Analysis
10

15

wise stated.

Example 16
In Vitro Utilization of GOS by Bifidobacteria and
Other Colonic Bacteria

A total of 39 strains of bifiodbacteria were screened for
25

Representative sequences from each OTU whose abun
dance was significantly influenced by GOS were subjected to
taxonomic classification using SeqMatch, an RDP web tool.
From each statistically significant OTU identified, five ran
dom representative sequences were aligned to form consen
sus sequences using SeqMan Software (DNASTAR Laser
gene). The consensus sequences were grouped and aligned
according to phylum (Actinobacteria, Bacteroidetes, Firmic
utes, Fusobacteria, Proteobacteria, and Verrucomicrobia),
together with the most closely related type strains or entry in
the NCBI database using Muscle 3.6 (Edgar, 2004, Nuc.
Acids Res., 32: 1792-7). Phylogenetic trees were assembled
by neighbor joining with 1,000 bootstrap replicates with
MEGA 4.0 Software (Tamura et al., 2007, Mol. Biol. Evol.,
24:1596-9). Using visual analyses and a distance matrix,
OTUs were assigned as sequence clusters with >97% identity,
and consensus sequences were generated for each of the OTU
sequence clusters, as described above.
Quantification of each OTU in each sample was performed
by BLASTn analysis with a local database including all the
quality controlled sequences generated by pyrosequencing. A
BLASTn algorithm was used with a 97% cutoff (min. length
300 bp) to quantify each OTU within each sample. The OTUs
that were closely related to Bifidobacterium adolescentis
were quantified by BLASTn using a cutoff of 98% (min.
length 300 bp) as clearly differentiated clusters could be
identified that showed overlap with 97%. The quantification
of OTUs in all subjects was then verified to ensure that indi
vidual sequences were not being assigned to different OTUS.
In three occasions, OTUs that were initially identified as
distinct had very high sequence similarities, and were thus
merged together as single OTUS.

To identify differences in the composition of the fecal
microbiota induced through dietary treatments (0.0g, 2.5 g.
5.0 g, and 10.0 g GOS) in all eighteen subjects, one-way
ANOVA tests with repeated measures were performed.
Samples obtained during the baseline and washout periods
were not included within the statistical analysis. Post hoc
pair-wise comparisons were done using Tukey's method.
P-values of <0.05 were considered significant unless other
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their ability to use GOS as a growth substrate. Included were
19 lab strains (from ATCC, commercial sources, and the
Department of Food Science Culture Collection) and 20 iso
lates obtained from subjects as described above. Strains were
grown anaerobically at 37°C. in MRS broth containing 2%
GOS (GTC Nutrition, Golden Colo.). Because the latter
material contains 92% GOS, with the balance as lactose,
glucose, and galactose, control cultures were prepared that
contained an equivalent amount of these Sugars (i.e., 0.16%
final concentration). In addition, twenty-two anaerobic bac
teria that were mainly of intestinal origin were also screened
for their ability to use GOS as a growth substrate. All bacteria
were obtained from the USDA ARS Culture Collection (Peo
ria, Ill.) and included strains of Bacteroides thetaiotamicron,
Bacteroides distasonis, Bacteroides fragilis, Bacteroides uni
formis, Bacteroides ovatus, Clostridium butyricum,
Clostridium histolyticum, Clostridium bifermentans,
Clostridium difficile, Clostridium innocuum, Clostridium
paraputrificum, Clostridium perfiringens, Clostridium ramo
sum, Clostridium rumen, Clostridium sporogenes, Entero
coccus faecalis, Enterococcus faecium, Enterobacter aero
genes, and Streptococcus salivarius. Bacteria were initially
propagated in Brain Heart Infusion (BHI) or Reinforced
Clostridial Agar (RCA). To assess growth on GOS, cells were
transferred (2%) into a basal medium 5 g/L Peptone No 3
(BD), 5.0 g/L Casitone (BD), 0.5 g/L L-Cysteine (Sigma), 40
mL Salt Solution, 10 mL Hemin (Sigma), 900 uLVitamin K3
(Sigma), and 1 g/L Yeast Extract (BD) containing 1% GOS
(GTC Nutrition, Golden, Colo.). Control cultures containing
0.08% mono- and disaccharides were prepared as above.
All cultures were incubated at 37°C. in an anaerobic cham
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Example 14

ber (Forma Scientific, Marietta, Ohio) containing an atmo
sphere of 85% nitrogen, 10% hydrogen, and 5% carbon diox
ide and assessed for growth by optical density measurement
at 600 nm in a Beckman Model 640 spectrophotometer. Each
experiment was done in triplicate and the average optical
densities were determined.

60

Determination of Community Diversity

Example 17

Two different methods, the generation of rarefaction
curves and Shannon's index, were applied to determine the
diversity of the fecal microbiota using 16S rDNA sequence
data. The DNA sequences within each sample were aligned
and clustered using RDP web tools Aligner and Complete

The Effect of GOS on the Fecal Microbial
Communities
65

A total of 288 fecal samples were included in this study.
Pyrosequencing resulted in a total of 2.3 million sequences.

US 9,125,935 B1
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After quality control analysis (see Methods), an average of
8,200 sequences per sample was obtained. The mean
sequence length was approximately 450 bp. An average of
2,022 OTUs was identified per subject. To assess the effect of
GOS on the bacterial diversity in fecal samples, rarefaction
curves for all eighteen Subjects were generated, and Shan
non's diversity indices were calculated. This analysis
revealed that consumption of GOS did not alter bacterial
diversity of the fecal samples (p<0.0713).
The overall composition of the gut microbiota in the 18
individuals included in this study is in general agreement with
that of previous studies (Turnbaugh et al., 2009, Nature, 457:
480-4). During the baseline period (no dietary modulation),
the microbiota was dominated by two phyla, Firmicutes
(64%) and Bacteroidetes (28%). Other phyla detected
included Actinobacteria (3%), Verrucomicrobia (1%), and
Proteobacteria (1%). Approximately 3% of the sequences

5
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treatment (0.0 g GOS in confections) had no effect on the
fecal microbiota, as the microbial populations during this
period were not significantly different from those during the
baseline and washout periods (although slight increases in the
family Bacteroidaceae and the genus Bacteroides were
detected). In addition, no significant changes in the fecal
microbiota were detected for a dose of 2.5g GOS. In contrast,
consumption of 5.0 g GOS led to several significant changes.
There were significant increases (p<0.05) in the family Bifi
dobacteriaceae and the genus Bifidobacterium compared to
the control dose. At the species level, the abundance of only
one OTU, corresponding to the species, Fecalibacterium
prausnitzii, increased significantly at this dose. In contrast,
significant decreases in abundance were observed at both the
family and genus levels for Bacteroidaceae (p<0.01) and
Bacteroides (p<0.01), respectively, at the 5.0 g dose com
pared to the control.
TABLE 6

Abundance of bacterial taxa affected by GOS consumption in fecal samples of eighteen
human Subjects as determined by pyrosequencing of 16S rRNA tags.
Proportion of bacterial taxa expressed in percentage (Meant SD

Baseline'

0.0 g’

2.5g

5.0 g’

10.0 g?

Washout

P value

Phylum
Actinobaceria

2.52

234

2.58

3.59

3.69

433

5.39

6.11

7.198.88

2.09 - 2.51 <O.OOO1

Family
Bifidobacteriaceae
Bacteroidaceae
Genus

Bifidobacterium
Bacteroides

1.56 2.14
12.22

1692.65

1.281.81
12.22

2SO - 3.43

4.275.18

7.43 15.03 - 10.66 13.299.24 11.209.11**

140 - 220

2.13 - 2.99

3.61 - 4.46

7.43 15.03 - 10.66 13.299.24 11.209.11**

6.14 + 7.08***S$
11.669.22**

5.20 + 6.18:: *S$
11.669.22**

1.24 + 2.10 <0.0001
13.698.27

OOO3O

1.05 + 1.82

0.0002

13.698.27 <O.OOO1

Species (OTUs)
bifidobacterium
adoiscentis
Bifiobacterium

O.37 - O.S6

O.34 - 0.89

0.46 - 0.86

0.85 - 1.09

1.03 - 1.SS*

O.21 - 0.48

OO1O

O.15 O.36

O.18 0.33

0.25 + 0.55

0521.13

0.77 - 141*S

O.12 0.25 <O.OOO1

O46 O.94

O.6O

0.76 - 172

1412.38

2.00 + 3.45*$

O.220.45 <O.OOO1

O.62 - 121

O.78 2.19

O.98

2.02

1823.30

2.50 + 4.55*$

O4O 0.92

OOO88

O.09: O23

O.09: 0.23

O.12

0.32

0.22

OSO

O.33

O.85*

O.15 - 0.38

O.O232

O.15

0.27- 0.88

0.56 - 138

0.51 - 1.16

O.91

2.08**

O.28

O.O1 OS

3.52 2.71

3.21

2.26

3.71 - 2.67

4.37 3.67

3.16 + 1.82

3.422.28 <O.OOO1

2.90

240

1.75

2.12

1.99 - 155

1.78

2.15 - 1.30 <O.OOO1

Ssp I
Bifidobacterium

153

spp II
Bifidobacterium

spp III
Bifidobacterium

longtin
Bifidobacterium
cantentiatin
Faecaibacterium

O.34

0.78

prailsnitzi
Coprococcits

2.04

1.24

1.11*

COile:S

Bacteria populations are averages of the two time points of the baseline period and the two time points of the washout 2 period.
*Bacteria populations are averages of all three time points of the feeding period,
Bacterial populations during the dietary treatments were compared to each other with repeated measures ANOVA and Tukey's posthoc test,
Significantly different to 0.00 g. *(p<0.05), **(p<0.01), ***(p<0.001).

Significantly different to 2.5g: Sop < 0.05), scp < 0.01).
Significantly different to 5.0 g.: f(p<0.05).
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remained unclassified. At the family level, the predominant
groups were the Lachnospiraceae (31%), Ruminococcaceae
(18%), Bacteroidaceae (12%), and Bifidobacteriaceae (2%).
The most common genera included Bacteroides (12.2%),
Fecalibacterium (7.7%), Blautia (7.4%), Ruminococcus
(3.7%), Roseburia (2.2%), Bifidobacterium (1.5%), and
Dorea (1.3%).
Sequence proportions determined by pyrosequencing were
used to determine the effect of GOS on the composition of the
gastrointestinal microbiota. The groups that were signifi
cantly affected are shown in Table 6, according to phylum,
family, genus (by RDP Classifier), and OTUs. The control
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At the 10.0 g GOS dose, additional differences in the
proportions of several phyla (using taxonomy-based analy
sis) were observed (Table 6). There was a significant increase
in Actinobacteria compared to the control (p<0.001), as well
as compared to the 2.5 g dose (p<0.05). This change was
associated with an increase both in the family Bifidobacteri
aceae, the genus Bifidobacterium, and several OTUs related
to Bifidobacterium species. Although there were not signifi
cant differences between the 5 gram and 10 gram dose in
Bifidobacteriaceae, the genus Bifidobacterium, and Bifido
bacterium species, the amount of bifidobacteria at 10 gram
GOS was consistently higher than at 5 gram. In addition,

US 9,125,935 B1
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bifidobacteria were significantly increased at 10 gram GOS
when compared to the 2.5 gram dose (Table 6). Collectively,
the abundances of bifidobacteria determined by pyrosequenc
ing were highly correlated (r–0.7629, p<0.0001) with the cell
counts obtained by qRT-PCR as described above. This sup
ports previous findings that show that the pyrosequencing
approach allows a quantitative determination of bifidobacte
ria in human fecal samples.
There were few bacterial taxa other than bifidobacteria that

were influenced by GOS, based on a taxonomy-based analy
sis (Table 6). Statistically significant decreases were observed
only within the family Bacteroidaceae (p<0.05) and the genus
Bacteroides (p<0.05) when compared to the control dose of
GOS. In contrast, the OTU-based approach identified two
additional taxa, Coprococcus comes and F. prausnitzii, whose
abundances differed significantly at 5 and 10g doses. How
ever, no trend was apparent from these results (Table 6).
Although few taxa were identified that significantly

10

15

decreased with the administration of GOS when all 18 sub

jects were assessed collectively, our analysis nonetheless
showed that different bacterial lineages were decreased in
individual subjects. As shown in FIG. 7, the changes were
detected in a small number of subjects and occurred primarily
within taxonomically diverse members within the phyla Fir
micutes (FIG.7A) and Bacteroidetes (FIG.7B). Most of these
taxa were reduced by GOS, but no consistent pattern was
detected among Subjects. Thus, it appears that although GOS
induces a rather selective increase of different lineages of

Temporal Dynamics of Microbial Populations in
Response to GOS
25

bifidobacteria, GOS does not resultina consistent increase of

another bacterial group or a significant decrease of particular
bacterial groups.
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Example 18
GOS Enhances Different Lineages of Bifidobacteria
A BLASTn analysis revealed that eight OTUs had statisti
cally significant changes in abundance at the 10g GOS dose,
six of which were assigned to the genus Bifidobacterium.
Three of the OTUs showed a high similarity (>97%) to
described Bifidobacterium species, B. adolescentis, B. lon
gum, and B. catenulatum (Table 6, FIG. 4A). The other OTUs
(Bifidobacterium spp I, II, and III) showed lower sequence
similarities (91-96%) to known Bifidobacterium species, and
the phylogenetic analysis shown in FIG. 4A revealed that
these OTUs belonged to lineages clearly distinct from known
type strains. Interestingly, two of these OTUs (Bifidobacte
rium spp II and Bifidobacterium spp III), showed the numeri
cally highest response to GOS (Table 6, FIG. 4A).
Example 19
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Analyses of the community profiles provided insight into
how GOS influenced the population dynamics over the entire
16 week study period. All of the changes induced by GOS
were reversible within one week, and no differences (Stu
dent's t-test, pc-0.05) could be detected in the proportions of
the bacterial groups between the first washout sample and the
baseline sample (FIG. 6). The temporal patterns of the three
main phyla (Actinobacteria, Bacteroidetes, and Firmicutes)
and two of the selected genera (Bifidobacterium and
Bacteroides) for five representative subjects showed that
these groups were stable in their temporal response to GOS.
For example, levels of Actinobacteria, Bacteroidetes, and
Firmicutes were remarkably stable in fecal samples at the
baseline and washout periods, and their populations returned
to the baseline level within one to two weeks after GOS

consumption was stopped. The same observations were also
made at the genus level for Bifidobacterium and Bacteroides.
Example 21
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In Vitro Growth of Gastrointestinal Microbiota
Cultures on the Prebiotic GOS

As shown above, GOS induces alterations to the human
50

fecal microbiota that are remarkably specific for bifidobacte
ria. However, GOS utilization was observed to be a strain

specific phenotype, at least based on in vitro growth studies
(Table 7). It was also considered whether or not the ability to
utilize GOS as a growth substrate was restricted to bifidobac

The Population Shifts Induced by GOS Vary Among
Individuals
55

Although the consumption of GOS at the higher doses
resulted in compositional shifts within Subjects on a collec
tive basis (FIG. 4B), closer examination of samples from
individual subjects revealed that the effect of GOS on the
intestinal composition of participants was Subject to consid
erable variation among individuals (FIG. 5). Indeed, the data
showed that there were some individuals that were essentially
unaffected by GOS consumption, whereas other experienced
significant changes. The most Substantial alteration was the
increase in the Actinobacteria (at the phylum, family, genus,
and species levels) which was observed in sixteen of the
eighteen subjects after 5.0 g and seventeen of the subjects

22
after 10.0 g of GOS. At the genus level, in particular, substan
tial increases were observed in the abundances of Bifidobac
terium, which increased approximately ten-fold (from 1-4%
up to 18-33%) in four subjects (subjects 2, 4, 11, and 17), and
five-fold in seven additional subjects (subjects 1, 9, 10, 15,
18). Several culturable isolates (NEGOS 1-3) were obtained
from these subjects and were found to associate within the
distinct Bifidobacterium spp. II lineage (FIG. 4A), indicating
that this GOS responding linage contains bacteria that can be
cultured. There was a very consistent reduction in the
Bacteroidetes (at the family, genus, and species levels), which
occurred within all of the subjects at some point after 5.0 g of
GOS was consumed (FIG. 5). At the genus level, there was a
decrease in the abundance of Bacteroides in 17 subjects after
the 5.0 g GOS dose (all except subject 4), with 14 of those
subjects having a further decrease after consumption of 10.0
g of GOS.
Example 20

teria and absent in other colonic bacteria. Therefore, the abil

ity of twenty-two strains of bacteria that are associated with
the human intestinal tract to utilize GOS was tested. This was
60

65

performed by comparing growth in media containing GOS
with growth in basal medium (i.e., without an additional
source of carbohydrate). This experiment revealed that 6 of
the 11 Clostridium strains could utilize GOS (FIG. 8), as
indicated by higher final cell densities compared to growth
without carbohydrates. In addition, three of the six strains of
Bacteroides were also significantly enriched when GOS was
present. Significant growth on GOS was not observed, how
ever, for Strains of the genera Enterococcus, Enterobacter, or
Streptococcus used in this study.
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TABLE 7

Species (total number)

Number

Number

positives (%)

negative (%)

6 (60)
5 (84)
1 (50)
1 (100)
2 (100)
6 (67)
2 (67)
3 (50)

4 (40)
1 (16)
1 (50)
O
O
3 (33)
1 (33)
3 (50)

B. adolescentis (10)
B. bifidum (6)
B. breve (2)
B. animalis Subsp. Lactis. (1)
B. longtim Subsp. Infantis (2)
Blongtim Subsp. longtim (9)
B. pseudocatentiatin (3)
Other Bifidobacterium spp. (6)
Total (39)

26 (67)

10

13 (33)

Part C

15

Example 22
Summary of Part A and Part B
Isolates of the genus Bifidobacterium were obtained from
responders while the Subjects were consuming 10 grams of
GOS. As shown in FIGS. 9A and 9B, 10 grams of GOS led to
an increase in the proportion of bifidobacteria in the fecal
samples of one subject from around 3% to around 20%, and
an increase of the Bifidobacterium spp. II lineage from around
3% to 10%, as determined by 16S rRNA tag pyrosequencing.
Absolute quantification using qRT-PCR confirmed that bifi
dobacteria numbers increased in the fecal samples of this
subject through the addition of GOS (FIG. 9C). From this
subject, three bacterial isolates were obtained from selective
agar plates (Rogosa SL. Agar) during the consumption of 10
gram GOS. All three isolates belong to the Bifidobacterium
spp. II lineage, which showed a marked increase through
GOS (FIG.9B) and two of these isolates represented the same
strain based on molecular typing. One isolate, BD1 (97%
homology to the type strain of Bifidobacterium adolescentis
when the entire 16S rRNA gene was analyzed), was tested for
its ability to ferment GOS. As expected for a lineage that
became enriched in vivo through the administration GOS,
strain BD1 showed a remarkable ability to utilize GOS, grow
ing as well as on lactose (FIG. 9D).
Example 23
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animalis subsp. lactis BB-12
Group 6: Prebiotic (5 gram GOS)

(after 8 hour fasting) at this visit. Endotoxin is only assessed
after aspirin challenge since previous research showed that
aspirin challenge was necessary to induce hyperpermeability
in susceptible obese individuals. Additional serum and
plasma is collected and stored in-80 freezer for future study
(measurement of lipid profile and insulin to calculate HOMA
index for metabolic syndrome and cytokines, CRP). Urine is
stored for future 12-hour cortisol measurements. Subjects are
provided with one of the six treatments (as determined by
randomization, see below), supplies for stool and urine col
lection identical to baseline. Subjects consume their ran
domly assigned Supplement daily for three weeks as
instructed. At the end of three weeks (within week 3), subjects
return to the clinic to provide stool, urine as previously
Supplementation, the Subjects provide the remaining urine
sample, and 3-day food records. Subjects provide fasting

40
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Heather Rasmussen. The trial includes six, 3-week treatments

Group 2: Probiotic 1: 10 cells of B. adolescentis BD1
Group 3: Probiotic 2: 10 cells of B. animalis subsp. lactis
BB-12.
Group 4: Synbiotic 1: InVivoSyn (5 gram GOS plus 10
cells of B. adolescentis BD1)
Group 5: Synbiotic 2: 5 gram GOS plus 10 cells of B.

In brief, the sugar cocktail is taken at 6 or 7 AM after an
overnight fast. Subjects collect allurine for 24 hours (first 12
hour in onejar and second 12 hour in secondjar). The Subject
repeats the Sugar cocktail ingestion and urine collection 12
hours after taking 2.6 gram of aspirin to induce intestinal
permeability. The subject is instructed to store the urine and
stool samples in Styrofoam coolers with freezer packs until
delivery to the hospital (not >than 3 days after collection). At
Visit 2, the study subject provides urine from the aspirin
challenge and the completed food record; Subjects also have

described for week 0-1. At the final visit after 3 weeks of

using obese (BMI=300-40.0 kg/m) subjects who are healthy
(but the study allows subjects with elevated liver enzymes due
to fatty liver and metabolic syndrome). Three-week treatment
length was selected to allow sufficient epithelial cell turnover.
A total of 180 subjects are recruited and randomly assigned to
six groups (n/group=30) as follows:
Group 1: Placebo (daily dose of 5 gram lactose)

shown in FIG. 10.

their blood drawn for CMP and endotoxin measurements

Research Design and Protocol
The study is organized as a randomized, placebo-con
trolled, parallel-arm clinical trial conducted at Rush Univer
sity Medical Center (RUMC) under the supervision of Dr.

24
Three visits are required from each subject. At Visit 1,
potential subjects are screened foreligibility and are provided
with a 3-day diet record, all supplies for stool and urine
collection (stoolkit, urine collection containers, Sugar cock
tail, and aspirin) and instructions for specimen handling and
for completing these tasks before the next visit. Each subject
collects the stool before taking the Sugar cocktail to avoid
potential effects of sugar cocktail on SCFA and microbiota
composition. Details of the stool and urine collection are

55

blood for endotoxemia and CMP measurements and stored

serum and complete questionnaires regarding adverse events
including a questionnaire that rates bowel movement, stool
consistency, discomfort, flatulence, abdominal pain, and
bloating on a scale from 1 (best) to 5 (worst). Weight, height,
waist circumference, and blood pressure is measured, and
BMI is calculated at each visit. Blood pressure is measured
using an automated cuff with the average of three assessments
used for statistical comparisons. In addition, stress is moni
tored at baseline and treatment end using the validated Per
ceived Stress Questionnaire as stress alone can increase per
meability. The necessary protocol approvals are obtained
from RUMC and UNL's Institutional Review Boards (IRB)
before initiation of the study, and subjects provide written
informed consent before any study procedures are performed.
Example 24
Subject Compliance and Education

60

65

A training session is held to explain the protocol to the
Subjects, how to consume the dietary items, the importance of
compliance, and the need for honesty if adherence to the
dietary treatment is not met. Subjects are provided with a
detailed explanation of the required commitment, and they
are encouraged to indicate to the clinical coordinator any
diversion from the dietary treatment and to return any prod
ucts that were not consumed. Regular interaction with the

US 9,125,935 B1
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Subjects by weekly phone calls is also encourage compliance.
Missing data is handled with the Last Observation Carried

26
Examples 28

Forward method.

Dietary Treatments
Examples 25

5

The two organisms that are used in this feeding study are B.
adolescentis BD1 and B. animalis BB-12. The latter is com

Subjects

Obese subjects (300-40.0 kg/m) are used for this study
because: (1) over /3 of the population is obese, and (2) these
individuals are predispositioned to hyperpermeability. An
equal number of both genders (50% each) are enrolled. It is an
aim to include approximately 40% minorities (30% African
American, 10% Hispanic or other minorities) in this study.
This enrollment of minorities is especially important because
obesity is especially preponderant in these minority groups.
Inclusion criteria include healthy subjects 18-60 years with

10

contains 1 g of cellpowder containing 10 CFU/g. In addition,

15

a BMI of 30.0-40.0 kg/m. Exclusion criteria include: (1)

prior intestinal resection, (2) patient history of GI diseases
except for hiatalhernia, GERD, hemorrhoids, (3) severe renal
disease defined by creatinine more than twice normal, (4)
markedly abnormal liver function defined by ALT/AST over
4 times normal levels or elevated bilirubin (5) antibiotic use
within the last 12 weeks prior to enrollment, (6) lean or

25

overweight (BMI<30 kg/m), (7) intolerant to aspirin, (8)

regular use of aspirin, (9) excessive alcohol intake (>2 drinks
for men or 1 drink for women daily), (10) presence of chronic
metabolic disease (cardiovascular disease, insulin requiring
diabetes or uncontrolled diabetes, cancer, (11) a plan to have
a major change in dietary habit during the following 6
months, (12) consumption of probiotics, prebiotics or Synbi
otics without an appropriate 4 week washout period, (13)
lactose intolerance or malabsorption; (14) subjects younger
than 18 or older than 60, and/or (15) unwillingness to consent
to the study.

30
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Examples 26
Randomization/Stratification/Blinding
The study participants are randomized (concealed, block
of 4) to one of the six treatment groups on their second visit
based on a computer-generated randomization. Randomiza
tion is stratified for gender and race to ensure equal numbers
of males and females and racial groups in each of the six

40
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treatments. The randomization is concealed and remains

blinded until completion of the study. The statistician also is
blinded, with the exception of having access to a subjects
identification numbers that belong to the six randomized
groups for analysis purposes. The study participants also are
blinded to the group assignment. The number of Sachets to be
taken daily and the shape of Sachets is identical in all six
groups. The Sachets are opaque and their contents are not
visible. Expectancy and credibility are measured in both pre
and post-treatment to determine the role that these factors
play in outcomes, and to confirm that the Subjects were

mercially available from Chrs. Hansen as a high cell density
powder. Strain BD1 is produced from a contract manufacturer
(Danwell Technology, Garden Grove, Calif.). Probiotic mix
tures subsequently are portioned into “sachets” in the Food
Processing Product Development Lab (UNL). Each sachet
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5.5 grams of lactose also is added as a carrier/control (see
below) for a total dose of 6.5 g. The sachet material is imper
meable to oxygen and moisture. The prebiotic, GOS, is
obtained from Corn Products International (sold under the
trade name, Purimune). This high purity GOS (>91%) con
tains less than 8% lactose. It was previously established that
a dose of 5g per day of this GOS was sufficient to induce a
bifidodogenic response and that a dose as high as 10 g/day did
not cause side-effects. The GOS is packaged in Sachets con
taining 5.5 g of Purimune (delivering 5 g of GOS) and an
additional 1.0 g of lactose, for a total dose of 6.5 g. Synbiotics
contain 5.5 g of Purimune and 1.0 g of probiotic, either
Bifidobacterium adolescentis BD1 or Bifidobacterium ani
malis BB-12, for a total dose of 6.5 g. Placebo samples
contain 6.5 g of lactose. Subjects are provided with enough
samples for the entire length of the study. Subjects are
instructed to consume each dose in a daily basis, either mixed
with food or liquid. The subjects are instructed to store
samples in a cool (<25°C.) environment.
Example 29
Analysis of Composition Fecal Microbiota
Frozen fecal samples are thawed and diluted in Phosphate
Buffered Saline (PBS) in a 1:10 ratio. DNA is isolated and gut
microbiota composition is analyzed by pyrosequencing of
16S rRNA tags. Briefly, total microbial DNA is isolated from
the fecal samples using a procedure that employs both enzy
matic and mechanical cell disruption. The V1-V3 region of
the 16S rRNA gene of the bacteria present in the fecal sample
is amplified by PCR from fecal microbial DNA by using a
combination of universal PCR primers that target the majority
of bacteria. The amplicons from each reaction is mixed in
equal amounts based on concentration and is subjected to
sequencing using a Roche Genome Sequencer GS-FLX using
the Titanium platform. This method results in around 300,
000-500,000 sequence reads per half-run after quality con
trol, and allows for a detailed characterization of the gut
microbiota via bioinformatic pipelines.
Example 30
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Determination of Absolute Cell Numbers of
Probiotic Strains and Total Bifidobacteria in Fecal

Samples

blinded.
60

Examples 27

formed to determine absolute cell numbers of the two strains

Power and Sample Size
65

Analysis showed that 40 subjects are needed for each group
to reach statistical significance (power-0.85; p<0.05).

Quantitative real-time PCR (qRT-PCR) is used to quantify
strains BD1 and BB-12 in human fecal samples. DNA is
isolated from human fecal samples and qRT-PCR is per
using qPCR with strain specific primers. The primers are
targeted towards strain specific sequences in the pan-genome
of the species. The genome of B. animalis subsp. lactis BB-12
is available, and the genomic sequence of B. adolescentis
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BD1 is currently being obtained. Total numbers of bifidobac
teria are determined by qRT-PCR. Absolute quantification by
qRT-PCR is performed in a Mastercycler realplex real-time
PCR system using standard curves generated with known cell
numbers of the two Bifidobacterium strains.
Example 31

28
large intestine it is also available in the lumen of colon for
absorption because, unlike lactulose and mannitol, it cannot
be metabolized and consumed by colonic bacteria.
Subjects fast overnight and Subsequently ingest a Sugar
mixture containing 2 grams mannitol. 7.5 grams lactulose, 40
mg Sucrose and 1 gram Sucralose in the morning, then collect
2 sequential 12-hour urinations (the first 12 hours for mea

Short-Chain Fatty Acid Analysis and Energy Content

ose). Urine is analyzed for Sugar content using gas chroma
tography (GC) techniques. Measurement of urinary Sugars
using GC is used to calculate intestinal permeability and is
expressed as percent oral dose excreted in the urine. A method
is used that involves conversion of the relevant sugars to their

Surement of lactulose and mannitol, and 24 hours for Sucral
10

Short-chain fatty acids (SCFA), including acetate, propi
onate, and butyrate, are identified by GC in the Analytical
Chemistry Lab in the Department of Food Science and Tech
nology at UNL.
Example 32
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Determination of Metabolic Activity of Probiotic
Strains in Human Fecal Samples
To determine if GOS increases the metabolic activity of the
Bifidobacterium strains in the human gastrointestinal tract,
both rRNA and rDNA templates in human fecal samples is
quantified using species specific primers. This determination
is based on the premise that metabolic activity in bacteria is
roughly proportional to the growth rate of the bacteria. While
DNA-based analytical procedures provide a phylogenetic
picture of the community, they do not reflect metabolic activ
ity. The higher the ratio between rRNA to rDNA templates in
fecal samples, the more metabolically active is the organism.
Total RNA (and especially ribosomal RNA) is isolated from
fecal samples. cDNA is prepared from DNAse treated RNA.
Template amounts are determined using qRT-PCR with spe
cific primers that target the 23S rRNA gene. The primers are
based on comparisons of 23 rRNA gene sequences from
Bifidobacterium adolescentis strains and sequences that are
available in database. This 23S rRNA gene sequence is vari
able in B. adolescentis, showing around 2% difference
between the strains ATCC 15703 and L2-32, allowing the
development of primers that are, at least to Some degree,
strain specific.
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While obese individuals are at an increased risk of hyper
permeability, increases in permeability may not be observed
unless challenged by other factors such as aspirin or alcohol.
In order to induce hyperpermeability, Subjects participate in
an aspirin challenge at baseline and the end of the 3-week
treatment. Four tablets, each containing 325 mg of aspirin, are
given 12 h before ingestion of the Sugar mixture and another
four tablets 1 h before taking the sugar drink. Measurement of
urinary Sugars using GC is identical to that of the Sugar test
without aspirin challenge.
Example 34
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Plasma and Serum Measures of Endotoxin Exposure
Increased intestinal permeability strongly correlates with
markers of increased exposure to endotoxin, a marker indi
cating increased oxidative stress burden in the intestine. To
determine if the increased permeability observed in the study

35
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Example 33
Intestinal Permeability Measurement

45

One way to assess intestinal permeability is by administra
tion of oral Sugars and analysis of subsequent Sugar excretion
in collected urine. Passageways ("pores') formed by tight
junctions between GI epithelial cells range in size from 4-60
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is associated with increased translocation of intestinal bacte

rial product, serum endotoxin and LPS-binding protein is
measured after aspirin challenge. In addition to the more
commonly-measured endotoxin, LPS-binding protein is
another index of intestinal permeability-related systemic
exposure to intestinal bacterial products. Endotoxin is mea
sured in serum by Limulus Amebocyte Lysate QCL-1000
(Lonza #50-647U). Serum samples are diluted at a 1:5 ratio
with LAL reagent water. Lipopolysaccharide binding protein
(LBP) is measured in plasma using an ELISA kit from Cell
Sciences Inc (H HK315).
Example 35
Serum Complete Metabolic Panel

A and differentially allow the passage of molecules. Small

molecules Such as mannitol traverse pores of all sizes, while
larger molecules, such as lactulose, only traverse the larger
pores. Sucrose is rapidly degraded after leaving the stomach,
so increased Sucrose excretion reflects gastric permeability
and Sucralose is absorbed through large pores in the Small and
large intestine. Since these Sugars are not metabolized sig
nificantly, excretion into the urine reflects intestinal perme
ability. Following ingestion of a standard Sugar load,
increased urinary Sucrose, lactulose/mannitol ratio and
Sucralose reflects gastroduodenal, Small intestinal and total
gut (Small bowel and large bowel) hyperpermeability, respec
tively. Increased Sucralose excretion in the face of normal
lactulose/mannitol ratio might reflect increased large intesti
nal permeability. The rationale for using urinary Sucralose as
a reliable marker of total gut permeability is that not only
sucralose is relatively uniformly absorbed in both small and

alditol acetate form.
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A Complete Metabolic Panel is performed to assess the
effect the treatments on each patient’s basic physiology. Mea
Surements include Sodium, potassium, chloride, CO., blood
urea nitrogen, creatinine, glucose, total protein, albumin, cal
cium, total bilirubin, alkaline phosphatase, aspartate amino
transferase, alanine aminotransferase, and anion gap.
Example 36
Test for Associations

Associations between host metabolic and immunological
markers, all taxa in the gut microbiota (analyzed at different
taxonomic levels) and Bifidobacterium populations are
assessed by multiple-correlation analysis using Pearson’s
correlation tests using GraphPad Prism software. Data that
does not conform to normal distribution and cannot be nor
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malized with mathematical transformations (i.e.: log 10,
square root) is analyzed with Spearmen’s rank correlations.
Example 37
Outcomes

The probiotic, GOS, or the synbiotic significantly contrib
utes to metabolic improvements when compared to the con
trol placebo. Decreased intestinal hyperpermeability occurs
in the InVivoSyn Synbiotic group over that of the commer
cially available synbiotic as well as the probiotics and prebi

10

otics alone. A decrease in endotoxemia and an increase in

LPS-binding protein is observed, as lower levels of plasma
LBP have been associated with increased exposure to gram
negative bacteria.
Either the probiotic, GOS, or the synbiotic significantly
contributes to metabolic improvements when compared to the
control placebo (lactose), and a correlation between the Bifi
dobacterium population and metabolic markers is detectable.
Example 38
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Statistical Analysis

30
Tukey's post hoc multiple comparisons tests. Apart from
understanding how each individual taxa is affected by the
treatments, a collective understanding of how these groups of
data are affected is investigated by multivariate analyses Such
as Principal Components Analysis (PCA). For the microbial
data, PCAS are constructed from a phylogenetic perspective
using UniFrac software. In addition, one-way ANOVA tests
followed by Tukey's post hoc tests are performed to identify
differences in population size and/or metabolic activity in the
different treatment groups, and especially between Synbiotic
and probiotic groups. Data is presented as meant-SEM for
variables that can be considered normally distributed (or
median and range for variables not normally distributed).
Group means is compared by ANOVA and post-hoc tests
except when data is not normally distributed, in which case
nonparametric analyses of medians is done using the
Kruskal-Wallis test. Correlation analysis is done using the
Pearson correlation test for parametric analysis and the Spear
man correlation test for nonparametric analysis. Chi-square
tests or Fisher's Exact Tests is used for incidence data. p <0.05
defines statistical significance. All analyses use SPSS (Chi
cago, Ill.) or SAS. Data that does not conform to normal
distribution and cannot be normalized with mathematical
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Statistical tests for treatment effects on the abundance of

individual taxonomic ranks is performed by one-way analysis
of variance (ANOVA) with repeated measures followed by

transformations (i.e., log 10, square root) is analyzed with
Freidman's non-parametric tests.
Sequence of 16S rDNA from microbial strain BD1 (SEQID
NO:8)

TGCAGTCGAA CGGGATCCCA GGAGCTTGCT CCTGGGTGAG. AGTGGCGAAC GGGTGAGTAA

TGCGTGACCG ACCTGCCCCA TACACCGGAA TAGCTCCTGG AAACGGGTGG TAATGCCGGA
TGCTCCAGTT GACCGCATGG TCCTCTGGGA AAGCTTTTGC GGTATGGGAT GGGGTCGCGT
CCTATCAGCT TGATGGCGGG GTAACGGCCC ACCATGGCTT, CGACGGGTAG CCGGCCTGAG
AGGGCGACCG GCCACATTGG GACTGAGATA CGGCCCAGAC TCCTACGGGA. GGCAGCAGTG
GGGAATATTG CACAATGGGC GCAAGCCTGA TGCAGCGACG CCGCGTGCGG GATGACGGCC
TTCGGGTTGT AAACCGCTCT TGACTGGGAG CAAGCCCTTC GGGGTGAGTG TACCTTTCGA
ATAAGCACCG GCTAACTACG TGCCAGCAGC CGCGGTAATA CGTAGGGTGC AAGCGTTATC
CGGAATTATT GGGCGTAAAG GGCTCGTAGG CGGTTCGTCG CGTCCGGTGT GAAAGTCCAT
CGCTTAACGG TGGATCCGCG CCGGGTACGG GCGGGCTTGA. GTGCGGTAGG GGAGACTGGA
ATTCCCGGTG TAACGGTGGA ATGTGTAGAT ATCGGGAAGA ACACCAATGG CGAaGGCAGG
TCTCTGGGCC GTCACTGACG CTGAGGAGCG AAAGCGTGGG GAGCGAACAG GATTAGATAC
CCTGGTAGTC CACGCCGTAA ACGGTGGATG CTGGATGTGG GGACCATTCC ACGGTCTCCG
TGTCGGAGCC AACGCGTTAA GCATCCCGCC TGGGGAGTAC GGCCGCAAGG CTAAAACTCA
AAGAAATTGA CGGGGGCCCG CACAAGCGGC GGAGCATGCG GATTAATTCG ATGCAACGCG
AAGAACCTTA. CCTGGGCTTG ACATGTTCCC GACAGCCGTA GAGATACGGT CTCCCTTCGG
GGCGGGTTCA CAGGTGGTGC ATGGTCGTCG TCAGCTCGTG TCGTGAGATG TTGGGTTAAG
TCCCGCAACG AGCGCAACCC TCGCCCTGTG TTGCCAGCAC GTCGTGGTGG GAACTCACGG
GGGACCGCCG GGGTCAACTC GGAGGAAGGT GGGGATGACG TCAGATCATC ATGCCCCTTA
CGTCCAGGGC TTCACGCATG CTACAATGGC CGGTACAACG. GGATGCGACA CTGTGAGGTG
GAGCGGATCC CTTAAAACCG GTCTCAGTTC GGATTGGAGT CTGCAACCCG ACTCCATGAA
GGCGGAGTCG CTAGTAATCG CGGATCAG
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It is to be understood that, while the methods and compo groups, etc. of these methods and compositions are disclosed.
sitions of matter have been described herein in conjunction That is, while specific reference to each various individual
with a number of different aspects, the foregoing description and collective combinations and permutations of these com
of the various aspects is intended to illustrate and not limit the positions and methods may not be explicitly disclosed, each is
scope of the methods and compositions of matter. Other specifically contemplated and described herein. For example,
aspects, advantages, and modifications are within the scope of if a particular composition of matter or a particular method is
the following claims.
disclosed and discussed and a number of compositions or
Disclosed are methods and compositions that can be used methods are discussed, each and every combination and per
for, can be used in conjunction with, can be used in prepara mutation of the compositions and the methods are specifically
tion for, or are products of the disclosed methods and com- 10 contemplated unless specifically indicated to the contrary.
positions. These and other materials are disclosed herein, and Likewise, any Subset or combination of these is also specifi
cally contemplated and disclosed.
it is understood that combinations, Subsets, interactions,
SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 8
<21 Os SEQ ID NO 1
&211s LENGTH: 18
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: Oligonucleotide
<4 OOs SEQUENCE: 1

togcgtcygg tdtgaaag

18

<21 Os SEQ ID NO 2
&211s LENGTH: 17
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: Oligonucleotide
<4 OOs SEQUENCE: 2

cca catccag crtccac

17

<21 Os SEQ ID NO 3
&211s LENGTH: 60
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: Oligonucleotide
<4 OOs SEQUENCE: 3

cgc.ccgcc.gc gC9C9gcggg C9ggg.cgggg gCacgggggg actCctacgg gaggcagcag

60

<21 Os SEQ ID NO 4
&211s LENGTH: 14
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: Oligonucleotide
<4 OOs SEQUENCE: 4

accgcggctg. Ctgg

14

<21 Os SEQ ID NO 5
&211s LENGTH: 50
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: Oligonucleotide
<4 OOs SEQUENCE: 5

Cct at CC cct gtgtgccttg gCagt ct cag agagtttgat Cmtggct cag

SO
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What is claimed is:

1. A foodstuff comprising (a) a composition comprising
Bifidobacterium adolescentis strain BD1 and GOS and a
pharmaceutically acceptable carrier selected from the group
consisting of a liquid carrier, a gel-based carrier, an oleagi
nous carrier, and an emulsion; and (b) yogurt.
2. A method for establishing or maintaining a healthy gas
trointestinal flora in an animal, said method comprising
administering, enterally, an effective amount of the foodstuff
of claim 1 to the animal,

10

thereby establishing or maintaining a healthy gastrointes
tinal flora in the animal.

3. The method of claim 2, wherein said animal is a human.
4. The method of claim 2, wherein said effective amount is

from about 10 CFU/day to about 10' CFU/day.

15

5. A method for reducing the effects of a gastrointestinal
disease in an animal, said method comprising administering,
enterally, an effective amount of the foodstuff of claim 1 to the
animal,

thereby reducing the effects of a gastrointestinal disease in
the animal.

6. The method of claim 5, wherein said animal is a human.
7. The method of claim 5, wherein said effective amount is

from about 10 CFU/day to about 10' CFU/day.
k

k

k

k

k
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